Tonghua Dongbao Insulin Aspart 30/50 filed for listing

On July 14, Tonghua Dongbao announced that two pre-mixed insulin aspart (insulin aspart 30 injection and insulin aspart 50 injection) have been accepted by CDE

Insulin aspart is a fast-acting insulin analogue.

Insulin Aspart 30 and Insulin 50 are both premixed insulins, both of which are composed of soluble insulin aspart and arginine insulin aspart, but the ratio is different

Insulin aspart 50 injection, the original drug NovoLog®, was developed by Novo Nordisk.

Tonghua Dongbao is a key high-tech enterprise of the Torch Program recognized by the Ministry of Science and Technology.

Tonghua Dongbao pipeline under development

Screenshot source: corporate website

In addition to Tonghua Dongbao, in China, Ganli Pharmaceutical, United Laboratories, and Shuanglu Pharmaceuticals are also research enterprises of insulin aspart

On May 14, 2020, Rui Xiulin, the third-generation insulin analogue of Ganli Pharmaceutical, was approved by the State Food and Drug Administration for listing, breaking the long-term monopoly of insulin aspart.

In May of this year, an investor asked Shuanglu Pharmaceutical about the clinical enrollment of insulin aspart 30 in phase III.

The Insulin Aspart 50 injection registered by United Laboratories was approved by the National Medical Products Administration for clinical trials on May 25, 2021, and was approved to carry out clinical trials for diabetes